Abstract
The goal of this rater-blinded randomized prospective comparative study was to assess the efficacy and side effects of haloperidol (H) and thioridazine (T) in the treatment of new-onset psychosis in HIV-infected patients. We studied 13 men (eight on H, five on T) with no history of psychosis prior to HIV infection and whose psychosis was not due to identifiable organic factors. Participants, seven of whom were in CDC stage C (AIDS), were evaluated before treatment and then weekly for six weeks. The mean dose in chlorpromazine equivalents was 124 mg/d. Both neuroleptics produced significant reduction of psychosis. All H-treated patients developed extrapyramidal side effects. Psychotic HIV-infected patients respond to neuroleptics but require and tolerate relatively low dosages.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sewell, D., Jeste, D., McAdams, L. et al. Neuroleptic Treatment of HIV-Associated Psychosis. Neuropsychopharmacol 11, 284 (1994). https://doi.org/10.1038/sj.npp.1380208
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.npp.1380208